A PYMNTS Company

Teva-Cephalon final order approved, resolving FTC concerns with three generics

By  |  July 3, 2012

The Federal Trade Commission has approved an amended final order resolving competition concerns with Teva’s proposed acquisition of Cephalon. The approved final order comes after a public consultation. The transaction affects the generics market for three drugs. Teva will have to sell the rights and assets related to a drug used to treat cancer pain (transmucosal fentanyl citrate lozenges) and a generic muscle relaxant (extended release cyclobenzaprine hydrochloride). These two drugs will be sold to Par Pharmaceuticals, Inc. Teva is also required to enter into a supply agreement allowing Par to sell a generic version of Provigil, which is used to treat narcolepsy and other sleep disorders, in 2012.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full content: FTC Press Release

     

    Related content: Reverse Payment Settlements: Presumptively Bad or Usually Acceptable?

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.